IN-VIVO EVALUATION OF RECOMBINANT HUMAN OSTEOGENIC PROTEIN (RHOP-1) IMPLANTS AS A BONE-GRAFT SUBSTITUTE FOR SPINAL FUSIONS
IN-VIVO EVALUATION OF RECOMBINANT HUMAN OSTEOGENIC PROTEIN (RHOP-1) IMPLANTS AS A BONE-GRAFT SUBSTITUTE FOR SPINAL FUSIONS
复制标题
DOI：
10.1097/00007632-199408000-00002
复制
发表时间：
1994-08-01
期刊：
影响因子：
3
通讯作者：
RUEGER, DC
中科院分区：
文献类型：
--
作者：
COOK, SD;DALTON, JE;RUEGER, DC
研究设计。成年杂种犬在植入后6、12和26周对后路脊柱融合节段进行评估。将重组人成骨蛋白-1植入骨胶原载体、单纯骨胶原载体、自体髂骨或不植入材料。目的：探讨重组人成骨蛋白-1作为植骨替代物在脊柱后路融合中的作用，并与自体骨移植的结果进行比较。后路脊柱融合术一般包括椎体表面去皮质后自体骨或同种异体骨的嵌套植骨。近年来，对可接受的骨移植替代材料的寻找集中在能够在体内诱导成骨的蛋白质上。重组人成骨蛋白-1在修复兔、狗和猴子的大段骨膜缺损方面显示出了有效性，并被认为是一种理想的脊柱融合的骨移植替代品。使用平片、计算机断层扫描和磁共振成像来评估融合和新骨形成的质量。放射学和组织学研究表明，重组人成骨蛋白-1处理的融合片段在植入后6周达到稳定融合，12周完全融合。结论：重组人成骨蛋白-1是一种有效的骨移植替代物，能以比自体骨移植更快的方式实现稳定的脊柱后路融合。
Study Design. Posterior spinal fusion segments were evaluated in adult mongrel dogs at 6, 12, and 26 weeks post-implantation. Four sites on each animal received implants consisting of recombinant human osteogenic protein-1 on a bone collagen carrier, bone collagen carrier alone, autogenous iliac crest bone, or no implant material.Objective, To determine the efficacy of recombinant human osteogenic protein-1 as a bone graft substitute in achieving posterior spinal fusion and compare the results to those obtained using autogenous bone graft.Summary of Background Data. Posterior spinal fusion generally includes onlay grafting of autogenous or allogeneic bone after decortication of bony surfaces of the vertebral elements. The search for an acceptable bone graft substitute material has in recent years centered upon proteins capable of inducing bone in vivo. Recombinant human osteogenic protein-1 has demonstrated efficacy in healing large segmental osteoperiosteal defects in rabbits, dogs, and monkeys and appears ideally suited as a bone graft substitute for spinal fusions.Methods. The quality of fusion and new bone formation was evaluated using plain films, computed tomography, and magnetic resonance imaging.Results. Radiographic and histologic studies demonstrated that recombinant human osteogenic protein-1-treated fusion segments attained a stable fusion by 6 weeks post-implantation and were completely fused by 12 weeks. The autograft sites demonstrated fusion at 26 weeks post-implantation.Conclusions, The results indicated that recombinant human osteogenic protein-1 is an effective bone graft substitute for achieving stable posterior spinal fusions in a significantly more rapid fashion than can be achieved with autogenous bone graft.